9,380
+0.97%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Reyon Pharmaceutical Co
Its shares trade on KRX under the ticker 102460.KS. It has been listed since 10 June 2010. In the fiscal year to 31 December 2025, it reported revenue of ₩145.93bn and a net loss of ₩29.63bn. At that date it held total assets of ₩465.10bn and shareholders' equity of ₩220.27bn.
REYON PHARMACEUTICAL Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Seoul, Seoul. The company went IPO on 2010-06-10. The Company’s products consist of remedies for circulatory systems, endocrine systems, digestive systems, respiratory systems, urinary systems and nervous systems, as well as eye drops, antibiotics, fever reducers, painkillers, anti-inflammatory drugs, antihistaminic agents, enzyme preparations, arthritis remedies, antitumor drugs and topical anesthetics, among others. The company also produces pharmaceutical raw materials, such as arbekacin sulfate, alibendol, carvedilol, enocitabine, gemcitabine, glimepiride, lamotrigine, meloxicam, oxaliplatin, pioglitazone hydrochloride, ramipril, streptokinase, tacrolimus, thioctic acid, teicoplanin, voglibose and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 10 Jun 2010
Leadership
Pay as last reported
- Ms. Sun Ok JungChairman, Co-Chief Executive Officer, since 2014
- Mr. Yong Hwan YooPresident, Co-Chief Executive Officer, Director
- Mr. Jong Hyeon ParkSenior Vice President, since 2021
- Mr. Ju Won ChoVice President
- Mr. Seok Jong ChoiManaging Director
- Mr. Yeong Min KimManaging Director
- Mr. Jin Yong SongManaging Director
- Mr. Byeong Ju LeeAssistant Managing Director
- Ms. Sun Ah LeeAssistant Managing Director
- Ms. Aeng Ran ParkAssistant Managing Director
- Mr. Jeong Taek ParkAssistant Managing Director
- Ms. Jeong Seop ShimAssistant Managing Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Seoul, South Korea
- Offers a diverse range of pharmaceutical products including remedies for multiple body systems
- Produces various pharmaceutical raw materials such as arbekacin sulfate and carvedilol
Weaknesses
- No specific weaknesses mentioned in the provided information
- The company's product range is described as extensive but no market share data is provided
- No mention of financial performance or growth metrics
Opportunities
- Expansion into new markets for pharmaceutical products
- Potential for increased demand in healthcare sectors
- Growth opportunities in the production of pharmaceutical raw materials
Threats
- No specific threats mentioned in the provided information
- Competition from other pharmaceutical companies is not detailed
- Regulatory changes in the pharmaceutical industry could impact operations
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.